Tallac Therapeutics Launches with $62 Million in Series A Financing to Advance Novel Immunotherapies for Cancer
~ Company Founded by Experienced Leaders with Track Record of Developing Successful Next-Generation Medicines for Cancer ~ December 01, 2020 07:00 AM Eastern Standard Time BURLINGAME, Calif.–(BUSINESS WIRE)–Tallac Therapeutics, Inc., a privately held biopharmaceutical company harnessing the power of innate and adaptive immunity to fight cancer, today announced the completion of its Series A financing […]
